In fact, about 5% of all breast cancers bear a BRCA1/2 germline pathogenic variant (PV) [6], being a tissue sensitive to PARP inhibitors [7], and thus treatment with this type of molecule is feasible. The gene discussed is BRCA1; the disease is breast cancer.